Acurx Pharmaceuticals Inc At Emerging Growth Conference Transcript
Welcome back, everyone. Next up, we have Acurx Pharmaceuticals, trades on the NASDAQ under the symbol ACXP and is a clinical-stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult-to-treat infections.
I would like to introduce David Luci, Co-founder, President and CEO of Acurx Pharmaceuticals. David is a serial entrepreneur who has co-founded or joined at the early stage of three biopharmaceutical companies prior to starting Acurx. All of which have been sold successfully, including the sale of Bioenvision to Sanofi in 2007; the sale of MacroChem Corp to Abeona -- I'm going to say that correctly hopefully -- Therapeutics Inc.; and the sale of Dipexium Pharmaceuticals to PLx Pharma, Inc.
Now, David has also raised over $220 million in equity offerings during his tenure in drug development and is an M&A and corporate securities attorney from Paul Hastings and CPA in the healthcare practice group of Ernst & Young as vocational background. So let's welcome David Luci.
How are you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
